• The market with the lowest expected future return is the United States which together with Canada and Denmark promises real returns that are quite a bit
lower than developed markets overall.
Not exact matches
In that vein, the company is very much a
market disruptor, and this is even true in
developed countries where it routinely releases Nexus phones and tablets with significantly
lower prices
than competitors.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger
than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings;
market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of
lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to
develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully
develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other
market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Consistent with FX, OTC interest rate derivative turnover is
lower in emerging
market Asia
than in
developed Asia.
Japanese funds have generated a
lower TVPI multiple
than other
developed markets, according to investment software firm eFront.
In short,
developed markets are more stable albeit with
lower growth prospects
than the emerging
markets.
he says frontier and emerging
markets provide ample opportunity for investors at much
lower valuations
than developed markets..
So, it actually makes complete sense that that number is too
low when you're talking about a
developed market economy versus an emerging economy because, in theory, a
developed economy can borrow at
lower rates
than an emerging economy can.
iShares MSCI ACWI
Low Carbon Target (CRBN): seeks to track the investment results of an index composed of large and mid-capitalization
developed and emerging
market equities with a
lower carbon exposure
than that of the broad
market.
More
than 70 % of the bonds in
developed -
market government bond indexes today have yields of 1 % or
lower, as the chart below shows.
International equity ETFs (both
developed and emerging
markets) are priced
lower than they were in 2007.
The International Fund may invest in emerging
markets, which are generally more volatile and can have relatively unstable governments, social and legal systems that do not protect shareholders, economies based on only a few industries and securities
markets that are substantially smaller, less liquid, more volatile and may have a
lower level of government oversight
than securities
markets in more
developed countries.
According to some key metrics, they actually appear stronger
than many
developed market countries — they have
lower debt burdens,
lower deficits, and higher reserves.
In short,
developed markets are more stable albeit with
lower growth prospects
than the emerging
markets.
In
developed ex U.S.
markets, profitability and
low beta are weaker in statistical significance
than in the United States.
Investing in emerging
markets may involve greater risks
than investing in
developed countries, including the possibility of industry concentration, nationalization, taxes and transaction costs,
lower trading volumes, and less liquid securities, resulting in higher volatility.
Price - to - earnings (P / E) ratios on the MSCI EAFE (representing
developed countries outside of the U.S.) and MSCI Emerging
Markets indices are approximately 40 - 60 %
lower than their U.S. counterparts.
EM earnings growth is 20 % year - on - year, and with positive earnings momentum and
lower valuations
than U.S. and European
developed markets, some analysts are bullish.
HBG's return also compares very favourably with other
developed market global bank indices, including the U.S., Japan, and Australia, and is in line with the U.K. and Canadian banks, but
lower than the European banks.
It's also more tax - efficient since it holds
developed markets stocks directly rather
than via an underlying ETF, which results in
lower foreign withholding taxes.
The iShares MSCI ACWI
Low Carbon Target ETF seeks to track the investment results of an index composed of large and mid-capitalization
developed and emerging
market equities with a
lower carbon exposure
than that of the broad
market.
Determined to take a better approach to pet nutrition
than what could be found on the
market at the time, Landa worked hand - in - hand with leading scientists to
develop Nulo's nutritional platform and grain - free formulas — all with high animal - based proteins,
low glycemic ingredients and a patented probiotic.
But they said New Mexico's ability to fully
develop its solar and wind resources depends more on regional
than internal
markets, given the state's
low consumption levels compared to its neighbors.
In 2015, IEA estimated that global fossil fuel consumption subsidies — used by many
developing countries to provide below -
market cost fuel to their citizens — totaled $ 320 billion, 35 percent
lower ($ 173 billion less)
than in 2014.
Center for American ProgressAccording to Project Catalyst, emission reductions on the
low end have improved largely due to countries such as Brazil and Indonesia strengthening their own direct commitments for reductions, rather
than, for example, only providing a less expensive offset
market through deforestation projects for
developed countries.
Certain foreign companies may be persuaded to accept contractual arrangements in India of a
lower standard
than they would typically accept in
developed markets.
Having a few
low - end and mid-range devices in its lineup is also a great way to grab consumers» interest in
developing markets, where purchasing power is
lower than in the West.
Extremely cheap payments: fees will
develop naturally, due to the free
market in an open and permissionless network and will fundamentally be
lower than on - chain payments